|Development phase||Fas 1|
|Expected filing with FDA||-|
|In-house or partnership||Partnership with Gesynta Pharma AB|
Cardiovascular morbidity and mortality are common in chronic inflammatory diseases due to vascular inflammation and endothelial dysfunction. The lead candidate drug, BI1029539, has been identified as a highly selective anti-inflammatory compound targeting microsomal prostaglandin E synthase (mPGES-1).
Selective deletion of mPGES-1 activity leads to anti- inflammatory, vasodilatory and platelet inhibitory effects.
The project is developed by Orexo´s partner Gesynta Pharma AB who owns all the rights to the project.